Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2006

01.11.2006 | Perspective

Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone

verfasst von: T. Kube, M. Sutter, R. Trittler, N. Feltgen, L. L. Hansen, H. T. Agostini

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

Intravitreal application of triamcinolone acetonide has become increasingly popular for the treatment of various retinal disorders. However, dosage, mode of preparation and application differ worldwide. The aim of this study was to find a safe vehicle that would allow intravitreal injection of an exact amount of triamcinolone acetonide without potentially retinotoxic preservatives.

Methods

Solutions of triamcinolone acetonide with a theoretical concentration of 4 mg/0.2 ml were prepared following one sedimentation (A) and two filtration (B, C) methods. In addition, a filtration method using carboxymethylcellulose 2% as a carrier (D) was established. During processing and after injection into an eye model, the crystals were quantified by weight and high-performance liquid chromatography (HPLC), and, hence, the rate of crystal loss during this process was determined.

Results

The initial preparation contained 93–106% of the calculated quantity. Method A, containing the entire vehicle, delivered 45%±7.3% of the target quantity to the eye model, whereas the vehicle-free methods B and C delivered 15%±6.9% and 11%±3.2%, respectively. Using carboxymethylcellulose 2% as a preservative-free vehicle, we found 93%±3.7% of the calculated amount in the eye model. The missing crystals were mainly sticking to the walls of the syringes and needles used for transfer.

Conclusion

Common methods for preparing triamcinolone acetonide vary in the amount of drug actually injected intravitreally. Carboxymethylcellulose is an ideal carrier substance for intravitreal application of an exact dose of triamcinolone acetonide without preservatives.
Literatur
1.
Zurück zum Zitat Alldredge CD, Garretson BR (2003) Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 23:113–116CrossRefPubMed Alldredge CD, Garretson BR (2003) Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 23:113–116CrossRefPubMed
2.
Zurück zum Zitat Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772CrossRefPubMed Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772CrossRefPubMed
3.
Zurück zum Zitat Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681–686CrossRefPubMed Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681–686CrossRefPubMed
4.
Zurück zum Zitat Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A (2003) Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 135:246–249CrossRefPubMed Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A (2003) Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 135:246–249CrossRefPubMed
5.
Zurück zum Zitat Berry GK, Reed JB (2005) The effect of sedimentation on the concentration of triamcinolone acetonide. Invest Ophthalmol Vis Sci 46:492– Berry GK, Reed JB (2005) The effect of sedimentation on the concentration of triamcinolone acetonide. Invest Ophthalmol Vis Sci 46:492–
6.
Zurück zum Zitat Burk SE, Da Mata AP, Snyder ME, Schneider S, Osher RH, Cionni RJ (2003) Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg 29:645–651CrossRefPubMed Burk SE, Da Mata AP, Snyder ME, Schneider S, Osher RH, Cionni RJ (2003) Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg 29:645–651CrossRefPubMed
7.
Zurück zum Zitat Bynoe LA, Weiss JN (2003) Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol 135:382–384CrossRefPubMed Bynoe LA, Weiss JN (2003) Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol 135:382–384CrossRefPubMed
8.
Zurück zum Zitat Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA (1998) Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 26:277–281CrossRefPubMed Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA (1998) Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 26:277–281CrossRefPubMed
9.
Zurück zum Zitat Conway MD, Canakis C, Livir-Rallatos C, Peyman GA (2003) Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 29:27–33CrossRefPubMed Conway MD, Canakis C, Livir-Rallatos C, Peyman GA (2003) Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 29:27–33CrossRefPubMed
10.
Zurück zum Zitat Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244–250CrossRefPubMed Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244–250CrossRefPubMed
11.
Zurück zum Zitat Degenring RF, Jonas JB (2003) Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol 87:361CrossRefPubMed Degenring RF, Jonas JB (2003) Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol 87:361CrossRefPubMed
12.
Zurück zum Zitat Degenring RF, Kamppeter B, Kreissig I, Jonas JB (2003) Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta Ophthalmol Scand 81:548–550CrossRefPubMed Degenring RF, Kamppeter B, Kreissig I, Jonas JB (2003) Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta Ophthalmol Scand 81:548–550CrossRefPubMed
13.
Zurück zum Zitat Fernandez-Vigo J, Refojo MF, Jumblatt M (1989) Elimination of hydroxypropyl methylcellulose from the anterior chamber of the rabbit. J Cataract Refract Surg 15:191–195PubMed Fernandez-Vigo J, Refojo MF, Jumblatt M (1989) Elimination of hydroxypropyl methylcellulose from the anterior chamber of the rabbit. J Cataract Refract Surg 15:191–195PubMed
14.
Zurück zum Zitat Fernandez-Vigo J, Refojo MF, Verstraeten T (1990) Evaluation of a viscoelastic solution of hydroxypropyl methylcellulose as a potential vitreous substitute. Retina 10:148–152PubMedCrossRef Fernandez-Vigo J, Refojo MF, Verstraeten T (1990) Evaluation of a viscoelastic solution of hydroxypropyl methylcellulose as a potential vitreous substitute. Retina 10:148–152PubMedCrossRef
15.
Zurück zum Zitat Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F (2003) A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121:667–673PubMedCrossRef Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F (2003) A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121:667–673PubMedCrossRef
16.
Zurück zum Zitat Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E (2002) Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86:247–248CrossRefPubMed Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E (2002) Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86:247–248CrossRefPubMed
17.
Zurück zum Zitat Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190–195PubMed Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190–195PubMed
18.
Zurück zum Zitat Ip M, Kahana A, Altaweel M (2003) Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. Semin Ophthalmol 18:67–73PubMedCrossRef Ip M, Kahana A, Altaweel M (2003) Treatment of central retinal vein occlusion with triamcinolone acetonide: an optical coherence tomography study. Semin Ophthalmol 18:67–73PubMedCrossRef
19.
Zurück zum Zitat Jonas JB (2002) Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. Br J Ophthalmol 86:1066CrossRefPubMed Jonas JB (2002) Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. Br J Ophthalmol 86:1066CrossRefPubMed
20.
Zurück zum Zitat Jonas JB, Sofker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132:425–427CrossRefPubMed Jonas JB, Sofker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132:425–427CrossRefPubMed
21.
Zurück zum Zitat Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84:1064–1067CrossRefPubMed Jonas JB, Hayler JK, Panda-Jonas S (2000) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84:1064–1067CrossRefPubMed
22.
Zurück zum Zitat Jonas JB, Hayler JK, Sofker A, Panda-Jonas S (2001) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 131:468–471CrossRefPubMed Jonas JB, Hayler JK, Sofker A, Panda-Jonas S (2001) Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 131:468–471CrossRefPubMed
23.
Zurück zum Zitat Jonas JB, Kreissig I, Degenring R (2002) Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 240:873–874CrossRefPubMed Jonas JB, Kreissig I, Degenring R (2002) Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 240:873–874CrossRefPubMed
24.
Zurück zum Zitat Jonas JB, Kreissig I, Degenring RF (2002) Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240:782–783CrossRefPubMed Jonas JB, Kreissig I, Degenring RF (2002) Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240:782–783CrossRefPubMed
25.
Zurück zum Zitat Jonas JB, Kreissig I, Degenring RF (2003) Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 136:384–386PubMedCrossRef Jonas JB, Kreissig I, Degenring RF (2003) Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 136:384–386PubMedCrossRef
26.
Zurück zum Zitat Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R (2003) Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 87:462–468CrossRefPubMed Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R (2003) Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 87:462–468CrossRefPubMed
27.
Zurück zum Zitat Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57–61CrossRefPubMed Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57–61CrossRefPubMed
28.
Zurück zum Zitat Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF (2004) Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122:218–222CrossRefPubMed Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF (2004) Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122:218–222CrossRefPubMed
29.
Zurück zum Zitat Karacorlu M, Ozdemir H, Karacorlu S (2003) Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 81:648–652CrossRefPubMed Karacorlu M, Ozdemir H, Karacorlu S (2003) Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 81:648–652CrossRefPubMed
30.
Zurück zum Zitat Kumagai K (2003) Introduction of a new method for the preparation of triamcinolone acetonide solution as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 23:881–882CrossRefPubMed Kumagai K (2003) Introduction of a new method for the preparation of triamcinolone acetonide solution as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 23:881–882CrossRefPubMed
31.
Zurück zum Zitat Liang C, Peyman GA, Serracarbassa P, Calixto N, Chow AA, Rao P (1998) An evaluation of methylated collagen as a substitute for vitreous and aqueous humor. Int Ophthalmol 22:13–18CrossRefPubMed Liang C, Peyman GA, Serracarbassa P, Calixto N, Chow AA, Rao P (1998) An evaluation of methylated collagen as a substitute for vitreous and aqueous humor. Int Ophthalmol 22:13–18CrossRefPubMed
32.
Zurück zum Zitat Martidis A, Duker JS, Puliafito CA (2001) Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 119:1380–1383PubMed Martidis A, Duker JS, Puliafito CA (2001) Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 119:1380–1383PubMed
33.
Zurück zum Zitat Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927CrossRefPubMed Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927CrossRefPubMed
34.
Zurück zum Zitat McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R (1981) The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 91:785–788PubMed McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R (1981) The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 91:785–788PubMed
35.
Zurück zum Zitat Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, Murray TG, Quiroz-Mercado H, Mieler WF (2003) Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 136:791–796CrossRefPubMed Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, Murray TG, Quiroz-Mercado H, Mieler WF (2003) Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 136:791–796CrossRefPubMed
36.
Zurück zum Zitat Nelson ML, Martidis A (2003) Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 14:39–43CrossRefPubMed Nelson ML, Martidis A (2003) Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 14:39–43CrossRefPubMed
37.
Zurück zum Zitat Nishimura A, Kobayashi A, Segawa Y, Sakurai M, Shirao E, Shirao Y, Sugiyama K (2003) Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina 23:777–779CrossRefPubMed Nishimura A, Kobayashi A, Segawa Y, Sakurai M, Shirao E, Shirao Y, Sugiyama K (2003) Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina 23:777–779CrossRefPubMed
38.
Zurück zum Zitat Park CH, Jaffe GJ, Fekrat S (2003) Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 136:419–425CrossRefPubMed Park CH, Jaffe GJ, Fekrat S (2003) Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 136:419–425CrossRefPubMed
39.
Zurück zum Zitat Parke DW (2003) Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 136:918–919CrossRefPubMed Parke DW (2003) Intravitreal triamcinolone and endophthalmitis. Am J Ophthalmol 136:918–919CrossRefPubMed
40.
Zurück zum Zitat Penfold PL (2002) Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br J Ophthalmol 86:600–601CrossRefPubMed Penfold PL (2002) Intravitreal triamcinolone in recurrence of choroidal neovascularisation. Br J Ophthalmol 86:600–601CrossRefPubMed
41.
Zurück zum Zitat Penfold PL, Gyory JF, Hunyor AB, Billson FA (1995) Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 23:293–298PubMed Penfold PL, Gyory JF, Hunyor AB, Billson FA (1995) Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 23:293–298PubMed
42.
Zurück zum Zitat Peyman GA, Cheema R, Conway MD, Fang T (2000) Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 20:554–555PubMed Peyman GA, Cheema R, Conway MD, Fang T (2000) Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 20:554–555PubMed
43.
Zurück zum Zitat Ranson NT, Danis RP, Ciulla TA, Pratt L (2002) Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 86:527–529CrossRefPubMed Ranson NT, Danis RP, Ciulla TA, Pratt L (2002) Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 86:527–529CrossRefPubMed
44.
Zurück zum Zitat Rechtman E, Allen VD, Danis RP, Pratt LM, Harris A, Speicher MA (2003) Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 136:739–741CrossRefPubMed Rechtman E, Allen VD, Danis RP, Pratt LM, Harris A, Speicher MA (2003) Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 136:739–741CrossRefPubMed
45.
Zurück zum Zitat Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA (2003) Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121:1279–1282CrossRefPubMed Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA (2003) Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121:1279–1282CrossRefPubMed
46.
Zurück zum Zitat Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Ishibashi T (2002) Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood–ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 240:423–429CrossRefPubMed Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Ishibashi T (2002) Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood–ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 240:423–429CrossRefPubMed
47.
Zurück zum Zitat Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517–1525CrossRefPubMed Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517–1525CrossRefPubMed
48.
Zurück zum Zitat Sutter FK, Gillies MC (2003) Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol 121:1491–1493CrossRefPubMed Sutter FK, Gillies MC (2003) Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol 121:1491–1493CrossRefPubMed
49.
Zurück zum Zitat Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 29:2–6CrossRef Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 29:2–6CrossRef
Metadaten
Titel
Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone
verfasst von
T. Kube
M. Sutter
R. Trittler
N. Feltgen
L. L. Hansen
H. T. Agostini
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2006
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-006-0326-2

Weitere Artikel der Ausgabe 11/2006

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2006 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.